Back

Acoramidis has a beneficial effect compared with placebo on change from baseline in NAC ATTR stage at month 30 in patients with ATTR-CM: results from the ATTRibute-CM study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Cardiac amyloidosis (1) Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Julian Gillmore

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Discussant - Cardiac amyloidosis (1)
Presentation thumbnail
The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and follow-up outcomes of patients with wild-type transthyretin amyloidosis: comparison of the pre- and post-bone scintigraphy eras in a Latin American center.
Miss P. Domenech (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, phenotype, and prognosis
Assistant Professor A. Zaroui (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Predictors of major adverse cardiovascular events in patients with wild-type transthyretin amyloid cardiomyopathy: insights from a regional hospital experience
Doctor A. Martins (Leiria, PT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Cardiac amyloidosis (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Acoramidis-mediated improvement in NT-proBNP at month 30 compared with placebo in patients with ATTR-CM: results from the ATTRibute-CM study
thumbnail
Congress Presentation
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources